Response Variability to Exercise

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age25-65
SponsorRobert Ross, PhD

About this trial

In this proposal, the investigators challenge the assumption that following the physical activity guidelines implies benefit for ALL adults, and that if benefit is not achieved in response to first line therapy, it will be by simply exercising more. Thus, for improving cardiorespiratory fitness and cardiometabolic risk factors, unanswered questions include: 1) To what extent, regardless of increasing exercise intensity or amount, is exercise not associated with benefit? Demonstration of a resistance to benefit through exercise in a substantial number of adults would be a novel and important finding, would counter the assumptions of many if not most health care practitioners, and could have immediate and direct application in all health care settings. 2) To what extent will non-responders to first line therapy (150 min/wk) be required to increase exercise intensity or amount to achieve benefit? 3) To what extent will failure to improve CRF segregate (be associate with) with cardiometabolic risk factors? The investigators propose that adults who remain exercise resistant for improvement in CRF and cardiometabolic risk despite increasing amount or intensity are at high risk of metabolic disease and consequently, are candidates for alternative treatment strategies.

Eligibility criteria

Qualifiers

Sedentary lifestyle (planned physical activity for one day per week or less).

Weight stable (± 2 kg) for 6 months prior to the beginning of the study.

BMI between 20 and 40 kg/m2.

Disqualifiers

Physical impairment which would make the intervention very difficult or unsafe according to doctor's advice.

Diabetes, current smokers.

Plan to move from the area in next 8 months.

Trial design

Treatments tested in this trial

  • Low amount, low intensity exercise
  • Low amount, high intensity exercise
  • High amount, high intensity exercise

Treatment groups

200 Participants
are divided into 4 treatment groups

Sponsors and collaborators

Robert Ross, PhD

Lead sponsor

Queen's University

Sponsor institution